250 related articles for article (PubMed ID: 16985092)
1. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Martina SD; Ismail MS; Vesta KS
Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092
[TBL] [Abstract][Full Text] [Related]
2. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
3. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
4. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
6. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E; Grootendorst DC; Brightling CE; Troy S; Qiu Y; Zhu J; Parker D; Matin D; Majumdar S; Vignola AM; Kroegel C; Morell F; Hansel TT; Rennard SI; Compton C; Amit O; Tat T; Edelson J; Pavord ID; Rabe KF; Barnes NC; Jeffery PK
Am J Respir Crit Care Med; 2003 Oct; 168(8):976-82. PubMed ID: 12816740
[TBL] [Abstract][Full Text] [Related]
7. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA
Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
[TBL] [Abstract][Full Text] [Related]
8. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
9. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
11. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
[TBL] [Abstract][Full Text] [Related]
12. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
14. Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell-Smith V; Cazzola M; Page CP
J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
16. Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Baeumer W; Szelenyi I; Kietzmann M
Expert Rev Clin Immunol; 2005 May; 1(1):27-36. PubMed ID: 20477652
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
Kroegel C; Foerster M
Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
[TBL] [Abstract][Full Text] [Related]
18. The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients.
Murphy DM; Ward C; Forrest IA; Pritchard G; Jones D; Stovold R; Fisher AJ; Cawston TE; Lordan JL; Corris PA
J Heart Lung Transplant; 2006 Dec; 25(12):1436-40. PubMed ID: 17178338
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
20. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
